semaglutide loss of exclusivity Off-patent in 2026: the next revolution in anti-obesity medications Patent Expiry Day: Novo Nordisk

They care about how the medication works for you, adjustment planning, and effective communication

Providers who submit PAs regularly learn to include the magic phrases: "failed 6-month medically supervised weight loss program," "documented BMI 32 with hypertension and prediabetes," "requesting Wegovy for treatment of obesity-related comorbidities." The coverage difference between Wegovy, Ozempic, and compounded semaglutide All three contain semaglutide, but Ambetter treats them as separate drugs with separate coverage rules: The loophole many patients attempt: ask the provider to prescribe Ozempic off-label for weight loss

FIGURE 1 Glucagon-like peptide-1 (GLP-1) is a polypeptide secreted by intestinal L cells, with its receptors widely distributed throughout the body

GLP-1 is an incretin hormone that enhances insulin secretion in response to meals and promotes satiety

What affects the cash price

Dose Adjustments : Patients with more severe kidney impairment may need lower doses or more frequent adjustments based on their response to the medication